Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

DongCheng Acquires Imaging Tracer to Predict Immunotherapy Efficacy

publication date: May 25, 2022

DongCheng Pharma, a Yantai imaging tracer company, acquired Greater China rights to commercialize a CD8 ImmunoPET agent developed by ImaginAb of Los Angeles. ImmunoPET’s CD8 agent (zirconium Zr 89 crefmirlimab berdoxam) is a Zr 89 -labelled Minibody that binds the CD8 receptor on human T cells. It offers quantitative, non-invasive PET imaging of CD8 T cells in patients, which diagnoses a patient’s immune status and predicts the efficacy of immunotherapies. Initially, the CD8 agent will start clinical trials led by a third party for China approval. ImaginAb will receive license and milestone payments plus royalties on sales. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital